Jhalak Singhal

This study shows that degrading host p38-MAPK with NR-7h reduces parasite load in Leishmania and Plasmodium infections and enhances antiparasitic therapy when combined with Amphotericin B.

This study evaluates a PROTAC molecule to degrade p38 MAPK in mosquitoes, disrupting Plasmodium falciparum development and enhancing immune gene expression, suggesting PROTACs as a novel strategy for malaria transmission control.

This paper evaluates PF-543, a SphK1 inhibitor, against Leishmania donovani, showing reduced parasite load and enhanced immune response both in vitro and in vivo.

This study identifies SphK1 as a druggable target in human macrophages for anti-leishmanial therapy by showing its role in promoting Leishmania donovani survival through immune evasion and cell fate regulation.

This study evaluates the immunopharmacological efficacy of Leishmania donovani overexpressing Ld_ζ1domain as a vaccine candidate against visceral leishmaniasis, showing reduced parasite burden and enhanced immune response.

The paper identifies PfTSEN1 as a tRNA splicing endonuclease in Plasmodium falciparum and demonstrates its inhibition by TSENi, a novel anti-malarial compound.

The paper reports a novel tRNA-derived peptide, tREP-18, with potent anti-leishmanial activity against L. donovani and PKDL isolates.